Table 2. Seroreactivity of Lyme disease patient serum against recombinant EF-Tu protein.
| Reactivitya | ||||
|---|---|---|---|---|
| Western blot | ||||
| Serum IDb | EF-Tua | ELISA | IgM | IgG |
| 902668 (C) | + | + | + | + |
| 920057 (D) | + | + | + | + |
| 911222 (E) | + | + | + | − |
| 902111 (F) | + | + | − | + |
| 911351 (G) | + | + | + | − |
| 910544 (H) | + | + | + | + |
| 911348 (I) | + | + | + | + |
| 910865 (J) | − | + | + | + |
| 931414 (K) | − | + | + | + |
| 910533 | − | + | + | + |
a
+: Seropositive and −: seronegative results. All Lyme disease patient samples tested positive to ELISA and/or Western blot. Sera from three healthy donors were used as negative controls for immunoblotting as indicated in material and methods.
b
Serum identification number used by the CDC Lyme disease evaluation panel, and letters in parentheses indicated strip identification from immunoblot results in Figure 1C.